Forbion European Acquisition Corp. (FRBN) is a Blank Checks company listed on NASDAQ. There were no new wire items for FRBN in the last 30 days. The most recent was published Feb 14, 2024.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
- 13D/GSEC Form SC 13G filed by Forbion European Acquisition Corp.SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
- 13D/GSEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
- 13D/GSEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
- SECSEC Form 15-12G filed by Forbion European Acquisition Corp.15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)
- SECForbion European Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
- 13D/GSEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
- INSIDERForbion Growth Sponsor Feac I B.V. returned 3,373,496 units of Class A Ordinary Shares to the company (SEC Form 4)4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
- INSIDERForbion Growth Sponsor Feac I B.V. converted options into 1,373,496 units of Class A Ordinary Shares (SEC Form 4)4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
- INSIDERNew insider Forbion Growth Sponsor Feac I B.V. claimed ownership of 2,000,000 units of Class A Ordinary Shares (SEC Form 3) (Amendment)3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)
- SECSEC Form 25-NSE filed by Forbion European Acquisition Corp.25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)
- NEWSWhy ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day SessionGainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ:EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ:VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ:HTCR)
- SECSEC Form 10-Q filed by Forbion European Acquisition Corp.10-Q - Forbion European Acquisition Corp. (0001874495) (Filer)
- NEWSWhy Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionGainers Abri SPAC I, Inc. (NASDAQ:ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ:NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share. BIO-key International, Inc. (NASDAQ:BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023. ReShape Lifesciences Inc. (NASDAQ:RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced p
- SECSEC Form 8-K filed by Forbion European Acquisition Corp.8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
- SECSEC Form DEFA14A filed by Forbion European Acquisition Corp.DEFA14A - Forbion European Acquisition Corp. (0001874495) (Filer)
- 13D/GSEC Form SC 13G filed by Forbion European Acquisition Corp.SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
- 13D/GSEC Form SC 13G filed by Forbion European Acquisition Corp.SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
- SECSEC Form DEFM14A filed by Forbion European Acquisition Corp.DEFM14A - Forbion European Acquisition Corp. (0001874495) (Filer)
- SECForbion European Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
- SECSEC Form 425 filed by Forbion European Acquisition Corp.425 - Forbion European Acquisition Corp. (0001874495) (Subject)
- SECForbion European Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
- PRenGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical OfficerBOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clinical development of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the development strategy for enGene's therapeutic pipeline of tissue-targeted non-viral gene therapies.
- SECSEC Form 10-Q filed by Forbion European Acquisition Corp.10-Q - Forbion European Acquisition Corp. (0001874495) (Filer)
- SECSEC Form 425 filed by Forbion European Acquisition Corp.425 - Forbion European Acquisition Corp. (0001874495) (Subject)
FRBN FAQ
7 questionsWhat does Forbion European Acquisition Corp. do?
Forbion European Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify opportunities in the life sciences industry in Europe. The company was incorporated in 2021 and is based in Wilmington, Delaware.What is the latest news on FRBN?
Quantisnow has not tracked any new filings, ratings or press releases for FRBN in the last 30 days. The most recent wire item was published on February 14, 2024.Where does FRBN stock trade?
Forbion European Acquisition Corp. (FRBN) is listed on NASDAQ.What sector and industry is FRBN in?
Forbion European Acquisition Corp. operates in the Finance sector, Blank Checks industry.When did Forbion European Acquisition Corp. go public?
Forbion European Acquisition Corp. (FRBN) completed its IPO in 2022.What companies are similar to FRBN?
Notable peers in the same industry include TACO (Berto Acquisition Corp.), INV (Innventure Inc.), PRE (Prenetics Global Limited), OXSQ (Oxford Square Capital Corp.), ILLU (Illumination Acquisition Corp I). Compare FRBN side-by-side with any of them on Quantisnow.How can I track FRBN on Quantisnow?
Quantisnow aggregates Forbion European Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FRBN to receive live email and push alerts on every new disclosure.